medigraphic.com
ISSN 1870-199X (Print)
Órgano oficial de la Facultad de Odontología, UNAM

2008, Number 3

<< Back Next >>

Rev Odont Mex 2008; 12 (3)

Botulinum toxin in muscular dystonia of the temporomandibular joint

Arellano FA, Picco DI

Language: Spanish
References: 30
Page: 142-148
PDF size: 170.91 Kb.


ABSTRACT

This investigation evaluated the effectiveness of the botulinum toxin type A in patients with temporomandibular joint dysfunction and oromandibular closing dystonia. Twenty persons were included between 29 and 61 years old, (90%) women, (10%) men. The trigger points were infiltrated, the pre-infiltration pain was measured with the analogous visual scale of the pain (AVS) and also weekly during 3 months. The mean value in the AVS of the initial pain was 8.15 points and for post-infiltration, the mean value was 3.7 points, with improvement of the pain of 45.3%. A new treatment with the botulinum toxin type A is proposed.


REFERENCES

  1. Marvin S, Brian F. Botulinum toxin a therapy for temporomandibular disorders. In: Brin Mitchell F, ed. Scientific and therapeutic aspects of botulinum toxin. Philadelphia PA: Lippincott Williams & Wilkins; 2002: 259-268.

  2. Glenn T. The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin. Department of Oral Biology and Medicine, School of Dentistry, University of California, Los Angeles, Los Angeles, CA. Phys Med Rehabil Clin N Am 2003: 727-748.

  3. Eng-Kin T, Ling-Ling C, Hui-Meng C. Severe bruxism following basal ganglia infarcts: insights into pathophysiology. J Neurol Sci 2004; 217(2): 229-32 2004010126

  4. Hyun J, Kwang-Won Y, Sam-Sun L, Min-Suk H, Kyle S. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg 2003; 29(5): 484-9.

  5. Marvin S, Brian F. The Crown Institute, Toronto, Ontario, Canada. Treatment of Temporomandibular Disorders with Botulinum Toxin. Clin J Pain 2002; 18 (6 Suppl): 5198-5203 ilkins, Inc., Philadelphia.

  6. Ada T. Treatment of masseteric hypertrophy. In: Hexsel D, ed. Cosmetic use of botulinum toxin. 1 ed. São Paulo Brazil: age Editoria; 2002: 185-186.

  7. Jeffrey A, Corinne H. Andrew B. Botulinum toxin for masseter reduction in Asian patients. Arch Facial Plast Surg 2004; 6: 188-191.

  8. Ron T, Joseph J. Botulinum Toxin Type A in the management of oromandibular dystonia and bruxism. In: Brin MF, ed. Scientific and therapeutic aspects of botulinum. Toxin Philadelphia PA: Lippincott Williams & Wilkins; 2002: 343-350.

  9. Joseph N., III, DDS. The use of botulinum toxin in cosmetic facial surgery. Oral and Maxillofacial Surgery Clinics of North America 2000.

  10. Frank S, John M, James R. Treatment of severe post-traumatic bruxism with botulinum toxin-A: Case report. J Oral Maxillofac Surg 2002; 60: 115-117.

  11. Joseph N. Botulinum toxin A: A review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg 2003; 61: 317-324.

  12. Martinez P, Ruiz E. Recurrent temporomandibular joint dislocation treated with botulinum toxin: Report of 3 cases. J Oral Maxillofac Surg February 2004: 62(2).

  13. Herzog W, Leonard TR. The history dependence of force production in mammalian skeletal muscle following stretch-shortening and shortening-stretch cycles. Journal of Biomechanics 2000; 33: 531-542.

  14. Quartaronea A, Girlanda P, Di Lazzaro V, Majorana G, Battaglia F, Messina C. Short latency trigemino-sternocleidomastoid response in muscles in patients with spasmodic torticollis and blepharospasm. Clinical Neurophysiology 2000; 111: 1672-1677.

  15. Hussain G, Manktelow RT, Tomat LR. Depressor labii inferioris resection: an effective treatment for marginal mandibular nerve paralysis. The British Association of Plastic Surgeons 2004; 57: 502-510.

  16. de Séze MP, de Séze M, Dehail P, Joseph PA, Lavignolle B, Barat M, Mazaux JM. Toxine botulique A et douleurs musculosqueletiques. Botulinum toxin A and musculoskeletal pain. Service de medicine physique et de readaptation, hospital Tastet-Girard-Pellegrin, CHU de Bordeaux France. Available online 13 August 2003.

  17. Dirk D. Prólogo de Michel F. Masson Doyma México. 1er Ed. 2003. Tratamiento con toxina botulínica

  18. Jeffre P. 4ª Ed. Harcourt brace 1999 España. Tratamiento de oclusión y afecciones temporomandibulares.

  19. Christopher F. Clinical Applications Botulinum Toxin: Implications for Pain Management.

  20. Welden B. Clinical management of temporomandibular disorders. Year Book Medical Publishers, Inc. Chicago London. 1er ed. 1982.

  21. Stephen B. Chronic temporomandibular joint arthralgia. Oral and Maxillofacial Surgery Clinics of North America.

  22. Hartmut G. Botulinum toxin A in pain management: Mechanisms of action and rationale for optimum use. In: Jost WH (ed): Botulinum toxin in painful diseases. Pain Headache. Basel, Karger, Kiel Pain Clinic, Kiel, Germany. 2003; 14: 14-22.

  23. Christopher R. Clinical Applications of Botulinum Toxin: Implications for Pain Management. Colorado Neurological Institute, Englewood, Colorado, USA. Pain Digest 1998; 8(6): 342-345.

  24. Mitchell F, William B, Andrew B, Lawrence S, Janice M. Botulinum toxin type A Botox® for pain and headache. Philadelphia PA: Lippincott Williams & Wilkips; 2002: 233-250.

  25. López del V, Castro G. Toxina botulínica: Aplicaciones terapéuticas. Masson. 1 Ed. 2002.

  26. Bell WE. Temporomandibular disorders. ed 3, Chicago. Year Book Medical Publishers. 1990: 60-61.

  27. Christensen LV, Mohamed SE, Harrison JD. Delayed onset of masseter muscle pain in experimental tooth clenching. J Prosthetic Dent 1982; 48(5): 579-84.

  28. Laskin DM. Etiology of the pain-dysfunction syndrome. J Am Dent Assoc 1969; 79(1): 147-53.

  29. Travell JG, Rinzler SH. The myofascial genesis of pain. Post Grad Med 1952;11: 425-34.

  30. Simons DG, Travell JG. Myofascial trigger points, a possible, explanation. Pain 1981; 10(1): 106-9.




2020     |     www.medigraphic.com